|Bid||293.82 x 1000|
|Ask||294.22 x 800|
|Day's Range||293.36 - 296.92|
|52 Week Range||281.89 - 543.55|
|PE Ratio (TTM)||28.44|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
There are a number of reasons that attract investors towards large-cap companies such as Regeneron Pharmaceuticals Inc (NASDAQ:REGN), with a market cap of US$32.52B. Market participants who are conscious ofRead More...
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18. On May 18, the stock closed at $3.46, a 119% increase from its 52-week low of $1.58 on May 19, 2017. On May 15, 2018, MEI Pharma stock closed at $3.40, a ~34.4% increase over the previous close of $2.53 on May 14, 2018. The stock rose ~58% in the last quarter.
Regeneron's experimental cancer drug "looks legit" in treating a form of lung cancer, an analyst said Thursday — meaning it could soon rival Merck and Bristol.
Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
Prices could improve a bit but a sustained advance will likely need a period of base building. In this daily bar chart of REGN, below, we can see that prices have been in a downtrend since last June. The daily On-Balance-Volume (OBV) line has also been weak and just made a new low for the move down.
Jim Cramer examines "the four horsemen of biotech" to see if their weakening stocks can regain momentum.
"Mad Money" host Jim Cramer examines "the four horsemen of biotech" to see if their weakening stocks can regain momentum. With a major market comeback underway, CNBC's Jim Cramer zeroed in on four key stocks in a sector that's not getting much love: biotechnology. Biogen BIIB , Celgene CELG , Regeneron REGN and Gilead GILD — some of the sector's most prominent names that Cramer labeled "the four horsemen of biotech" — have become outright hated by investors.
In April 2018, the FDA accepted for priority review Regeneron Pharmaceuticals (REGN) and Sanofi’s (SNY) Biologics License Application (or BLA) for cemiplimab for the treatment of individuals with metastatic CSCC (cutaneous squamous cell carcinoma) or individuals with locally advanced CSCC who cannot be treated with surgery. In September 2017, the FDA granted cemiplimab Breakthrough Therapy designation status for the treatment of metastatic CSCC. The FDA provided a Prescription Drug User Fee Act action date of October 28, 2018.
In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17, which reflected a ~20% rise on a YoY (year-over-year) basis.
In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17, which reflected a ~67% rise on a YoY (year-over-year) basis and a ~5% rise quarter-over-quarter.
Regeneron Pharmaceuticals (REGN) reported its 1Q18 earnings results on May 3. It generated revenue of $1.5 billion in the quarter compared to $1.3 billion in 1Q17, which reflected a ~15% rise on a YoY (year-over-year) basis and a ~4% fall quarter-over-quarter.
In 1Q18, Amgen’s (AMGN) Repatha revenue grew 15% YoY (year-over-year) to $123 million from $49 million, primarily due to higher unit demand. It grew ~26% quarter-over-quarter. In US and international markets, Repatha generated revenue of $84 million and $39 million, respectively, compared with $33 million and $16 million in 1Q17.
The health system will begin a 1,000-patient pilot program in six months, then role its DNA sequencing program out systemwide in Pennsylvania and New Jersey
As per the terms of the agreement, Exelixis and Invenra will jointly discover and develop antibodies with the help of Invenra’s B-Body technology platform, which allows high-throughput screening along with in vitro and in vivo preclinical characterization for the development of potential therapeutic candidates. According to the terms of the agreement, Exelixis will lead preclinical trials, manufacturing, the clinical development of both single-regimen and combination-regimen therapies along with regulatory filling and commercialization. Also under this collaboration, Exelixis and Invenra plan to conduct up to six discovery projects.
In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million yesterday, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...
Regeneron reported better-than-expected adjusted earnings of $4.76 a share. The biotech's revenue of $1.51 billion came in a little below some forecasts.